Interview: Why Europe’s Biotech ‘Prime Time’ Is Now
VC Firm Sofinnova’s Chair Papiernik Speaks After New Fund Launch
Executive Summary
The chairman of Sofinnova Partners told Scrip his newly launched biotech start-up fund aims to profit from Europe’s top science, relatively realistic asset prices, and geopolitical position between the US and China.
You may also be interested in...
Woodford Debacle Is A Test Of UK Biotech’s Resilience
As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.
BetterLife/Altum Merger ‘Triggered By Early COVID-19 Promise’
Created when BetterLife bought Altum at end-July, the merged entity will now focus on advancing the acquired group’s lead asset, an inhaled form of its patented interferon a2b product, as an early treatment for COVID-19.
Roche’s Etrolizumab Failure ‘Removes Big Pipeline Opportunity’
Roche’s etrolizumab missed primary endpoints in its Phase III study program evaluating it as maintenance therapy in moderately to severely active ulcerative colitis, a new therapeutic area for the firm.
Need a specific report? 1000+ reports available
Buy Reports